HOSPITAL UNIVERSITARIO RUBER
Departamento
Centro Nacional de Investigaciones Oncológicas
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Centro Nacional de Investigaciones Oncológicas (8)
2022
-
Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A
Nature Communications, Vol. 13, Núm. 1
2020
-
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
Breast Cancer Research, Vol. 22, Núm. 1
-
Randomized phase 0/I trial of the mitochondrial inhibitor Me-344 or placebo added to bevacizumab in early HER2-negative breast cancer
Clinical Cancer Research, Vol. 26, Núm. 1, pp. 35-45
2017
-
18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial
Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441
-
Critically short telomeres and toxicity of chemotherapy in early breast cancer
Oncotarget, Vol. 8, Núm. 13, pp. 21472-21482
-
Modulation of telomere protection by the PI3K/AKT pathway
Nature Communications, Vol. 8, Núm. 1
-
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition
Oncogene, Vol. 36, Núm. 19, pp. 2737-2749
2013
-
Lkb1 Loss Promotes Tumor Progression of BRAFV600E-Induced Lung Adenomas
PLoS ONE, Vol. 8, Núm. 6